Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Associate Director
USA
36+ years of experience
Laura Runkel 17 Jun 2022
For a deeper look into the data behind last year’s completed clinical trials and the trends driving them, Listen to the Completed Clinical Trials 2017: Status Quo or No?
Laura Runkel 27 Nov 2020
Tap into expert analysis of the trends and what they mean for the future of pharma with Citeline’s latest whitepaper, 2019 Completed Trials: The Beat Goes on for Industry Sponsored Trial Activity.
Trialtrove
By Laura Runkel 18 Oct 2019
Trialtrove recently released a major enhancement that indexes primary and secondary endpoints evaluated in clinical trials.
Trialtrove
By Laura Runkel 02 Jul 2019
The geographic scope of industry sponsored clinical trial activities has gone global. Successful programs require putting all the pieces together to ensure efficient enrollment of the target patients at high quality facilities to reliably execute detailed study protocols. Myriad differences between countries, including disease epidemiology, standard of care options, and logistical factors around medical facilities and practices, create challenges to making the right geographic choices.
Topic Clinical Trials
Trialtrove
By Laura Runkel 19 Oct 2018
Explore the current and future outlook for rheumatoid arthritis (RA) treatments. Such treatments remain ineffective for the 33% of RA sufferers who are or become unresponsive to treatment, resulting in a high interest in RA drug development to address this unmet need in the marketplace.
Trialtrove
By Laura Runkel 19 Jun 2017
Biosimilars for autoimmune drugs, including humira, remicade, etanercept, rituximab and others, have been in clinical development for several years.
Topic Biosimilars
Trialtrove
By Laura Runkel 09 Jan 2017
The past year has seen the approval of the first biologic drugs for the treatment of severe eosinophilic asthma, the anti-IL5 antibodies Cinquar (Teva) and Nucala (GlaxoSmithKline, GSK).
Laura Runkel 29 Jan 2016
Citeline’s Trialtrove has recently expanded its disease coverage to include trials evaluating therapeutic treatments for neonatal brain injury.
Laura Runkel 24 Oct 2014
The recent discontinuation of Eli Lilly’s tabalumab quickly followed the completion of two pivotal trials, ILLUMINATE 1 and 2.
Laura Runkel 01 Jan 2014
A report on the treatment of chronic obstructive pulmonary disease (COPD)
Pink Sheet
16 Feb 2016
Scrip
16 Dec 2015
Pink Sheet
15 Dec 2015
Pink Sheet
17 Nov 2015
Pink Sheet
26 Oct 2015
Pink Sheet
21 Oct 2015
Pink Sheet
14 Oct 2015
Pink Sheet
03 Sep 2015
Pink Sheet
14 Aug 2015
Pink Sheet
12 Aug 2015
Pink Sheet
12 Aug 2015
Pink Sheet
22 Jul 2015
Pink Sheet
13 Jul 2015
Pink Sheet
17 Jun 2015
Pink Sheet
16 Jun 2015
